Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer

por Nemunaitis, John, Stanbery, Laura, Walter, Adam, Rocconi, Rodney, Stephens, Philip
Publicado 2023

BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target

por Morand, Susan, Stanbery, Laura, Walter, Adam, Rocconi, Rodney P, Nemunaitis, John
Publicado 2020

Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer – Navigating maintenance therapy for homologous recombinant proficient ovarian cance...

por Goldsberry, Whitney N., Norquist, Barbara S., Rocconi, Rodney P., Modesitt, Susan C., Urban, Renata R.
Publicado 2022

GLI1 upregulates C-JUN through a specific 130-kDa isoform

por AMABLE, LAUREN, GAVIN, ELAINE, KUDO, KENJI, MENG, ERHONG, ROCCONI, RODNEY P., SHEVDE, LALITA A., REED, EDDIE
Publicado 2013

Racial health disparities in ovarian cancer: not just black and white

por Srivastava, Sanjeev K., Ahmad, Aamir, Miree, Orlandric, Patel, Girijesh Kumar, Singh, Seema, Rocconi, Rodney P., Singh, Ajay P.
Publicado 2017

Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.

por Mani, Chinnadurai, Tripathi, Kaushlendra, Chaudhary, Sandeep, Somasagara, Ranganatha R., Rocconi, Rodney P., Crasto, Chiquito, Reedy, Mark, Athar, Mohammad, Palle, Komaraiah
Publicado 2021

Allyl isothiocyanate induces replication-associated DNA damage response in NSCLC cells and sensitizes to ionizing radiation

por Tripathi, Kaushlendra, Hussein, Usama K., Anupalli, Roja, Barnett, Reagan, Bachaboina, Lavanya, Scalici, Jennifer, Rocconi, Rodney P., Owen, Laurie B., Piazza, Gary A., Palle, Komaraiah
Publicado 2015

In vitro chemoresponse in metachronous pairs of gyneclologic cancers

por Dalton, Heather J, Fiorica, James, McClure, Candace K, Rocconi, Rodney P, Recio, Fernando O, Levocchio, John L, Burrell, Matthew O, Monk, Bradley J
Publicado 2014

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

por Rocconi, Rodney P., Stanbery, Laura, Madeira da Silva, Luciana, Barrington, Robert A., Aaron, Phylicia, Manning, Luisa, Horvath, Staci, Wallraven, Gladice, Bognar, Ernest, Walter, Adam, Nemunaitis, John
Publicado 2021

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance

por Oh, Johnathan, Barve, Minal, Senzer, Neil, Aaron, Phylicia, Manning, Luisa, Wallraven, Gladice, Bognar, Ernest, Stanbery, Laura, Horvath, Staci, Manley, Meghan, Nemunaitis, John, Walter, Adam, Rocconi, Rodney P.
Publicado 2020

ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling

por Meng, Erhong, Mitra, Aparna, Tripathi, Kaushlendra, Finan, Michael A., Scalici, Jennifer, McClellan, Steve, da Silva, Luciana Madeira, Reed, Eddie, Shevde, Lalita A., Palle, Komaraiah, Rocconi, Rodney P.
Publicado 2014

RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance

por Somasagara, Ranganatha R., Spencer, Sebastian M., Tripathi, Kaushlendra, Clark, David W., Mani, Chinnadurai, da Silva, Luciana Madeira, Scalici, Jennifer, Kothayer, Hend, Westwell, Andrew D., Rocconi, Rodney P., Palle, Komaraiah
Publicado 2017

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

por Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John
Publicado 2023

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

por Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John
Publicado 2022

Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer

por Miree, Orlandric, Srivastava, Sanjeev Kumar, Khan, Mohammad Aslam, Sameeta, Fnu, Acharya, Srijan, Ndetan, Harrison, Singh, Karan Pal, Hertweck, Kate Louise, Dasgupta, Santanu, da Silva, Luciana Madeira, Rocconi, Rodney Paul, Carter, James Elliot, Singh, Seema, Singh, Ajay Pratap
Publicado 2021

Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer

por Kucera, Calen W., Tian, Chunqiao, Tarney, Christopher M., Presti, Cassandra, Jokajtys, Suzanne, Winkler, Stuart S., Casablanca, Yovanni, Bateman, Nicholas W., Mhawech-Fauceglia, Paulette, Wenzel, Lari, Hamilton, Chad A., Chan, John K., Jones, Nathaniel L., Rocconi, Rodney P., O’Connor, Timothy D., Farley, John H., Shriver, Craig D., Conrads, Thomas P., Phippen, Neil T., Maxwell, G. Larry, Darcy, Kathleen M.
Publicado 2023